All In MedTech

Device Trial Radar · NCT04653961

Evaluation of a Decision Support System for People With Diabetes Who Use Multiple Daily Insulin Injections- Feasibility and Proof of Concept Studies

Last checked: Nov 19, 2026Latest source record: Mar 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

48

Planned (sponsor's estimate)

Start

Jun 1, 2020

Primary completion

Oct 2025

Study completion Oct 2025

Sponsor

Lead sponsor
Rabin Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The Leona M. and Harry B. Helmsley Charitable Trust; DreaMed Diabetes
First posted
Dec 4, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 14 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study comprises of two segments: a feasibility segment and a Proof of Concept segment. The study is open label, prospective study that will include up to 72 subjects in segment 1 and up to 40 subjects in segment 2. Participants are people with Type 1 or type 2 Diabetes treated with Multiple Daily Injections ( MDI) and Self Monitoring of Blood Glucose (SMBG) or intermittent Continuous Glucose Monitoring (CGM). The study will include screening, a 2-4-week run-in period and 10-12 weeks intervention period. Subjects will be asked to record their insulin delivery during basal/bolus insulin treatment (using dedicated apps ) and their daily activities (meals, physical activity etc.) using electronic log (implemented on Dedicated Apps), for a total period of 12-16 weeks. The goal of this study is to evaluate the safety of a decision support system for adjustment of insulin treatment plan for people with diabetes using multiple daily injections and monitoring glucose by SMBG or intermittent CGM

Conditions

  • Type1diabetes

Interventions

  • DreaMed Advisor Pro DSS-MDI algorithmDevice

    The DreaMed Advisor Pro software is a proprietary algorithm, designed to provide a comprehensive analysis of individual diabetes data which consists of glucose levels and insulin delivery history. the Advisor Pro algorithm identifies glucose patterns and their possible causes, which may hamper the patient's glucose control, and recommend on adjustment to the patient-specific insulin treatment profiles as well as suggestions for personalized diabetes management tips (such as timing of meal boluses, bolus delivery compliance and personalized glucose targets).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sensor glucose percentage of time in hypoglycemia below 54 mg/dlTime frame: 12-16 weeks
  2. Sensor glucose percentage of time in hyperglycemia above 250 mg/dlTime frame: 12-16 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • schneider children medical center of Israel

    Petah Tikva, Israel · Recruiting

  • Rabin Medical Center- Belinson

    Petah Tikva, Israel · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.